Related Experiment Video
Updated: Aug 9, 2026
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway
Chalet Tan1, Rita G de Noronha, Anthony J Roecker
1Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA 30322, USA.
Abstract:
Hypoxia-inducible factor 1 (HIF-1) is the central mediator of cellular responses to low oxygen and has recently become an important therapeutic target for solid tumor therapy. Inhibition of HIF-1 is expected to result in the attenuation of hypoxia-inducible genes, which are vital to many aspects of tumor biology, including adaptative responses for survival under anaerobic conditions. To identify small molecules inhibiting the HIF-1 pathway, we did a biological screen on a 10,000-membered natural product-like combinatorial library. The compounds of the library, which share a 2,2-dimethylbenzopyran structural motif, were tested for their ability to inhibit the hypoxic activation of an alkaline phosphatase reporter gene under the control of hypoxia-responsive elements in human glioma cells. This effort led to the discovery of 103D5R, a novel small-molecule inhibitor of HIF-1alpha. 103D5R markedly decreased HIF-1alpha protein levels induced by hypoxia or cobaltous ions in a dose- and time-dependent manner, whereas minimally affecting global cellular protein expression levels, including that of control proteins such as HIF-1beta, IkappaBalpha, and beta-actin. The inhibitory activity of 103D5R against HIF-1alpha was clearly shown under normoxia and hypoxia in cells derived from different cancer types, including glioma, prostate, and breast cancers. This inhibition prevented the activation of HIF-1 target genes under hypoxia such as vascular endothelial growth factor (VEGF) and glucose transporter-1 (Glut-1). Investigations into the molecular mechanism showed that 103D5R strongly reduced HIF-1alpha protein synthesis, whereas HIF-1alpha mRNA levels and HIF-1alpha degradation were not affected. 103D5R inhibited the phosphorylation of Akt, Erk1/2, and stress-activated protein kinase/c-jun-NH(2)-kinase, without changing the total levels of these proteins. Further studies on the mechanism of action of 103D5R will likely provide new insights into its validity/applicability for the pharmacologic targeting of HIF-1alpha for therapeutic purposes.
Insights
Researchers discovered 103D5R, a novel small molecule that inhibits Hypoxia-Inducible Factor 1-alpha (HIF-1α) protein synthesis. This compound shows potential for targeting solid tumors by blocking key hypoxia-inducible genes like VEGF.
Area of Science:
- Molecular Biology
- Cancer Therapeutics
- Biochemistry
Background:
- Hypoxia-Inducible Factor 1 (HIF-1) is a crucial mediator of cellular responses to low oxygen environments.
- HIF-1 plays a significant role in tumor biology and is a key therapeutic target for solid tumor treatment.
- Inhibiting HIF-1 can attenuate hypoxia-inducible genes essential for tumor survival and adaptation.
Purpose of the Study:
- To identify novel small molecules that inhibit the HIF-1 pathway.
- To discover inhibitors targeting HIF-1α, a central component of the HIF-1 pathway.
- To investigate the therapeutic potential of identified inhibitors in various cancer types.
Main Methods:
- A biological screen of a 10,000-membered natural product-like combinatorial library was performed.
- Compounds were tested for inhibition of hypoxic activation of a reporter gene in human glioma cells.
- The novel inhibitor 103D5R was characterized for its effects on HIF-1α protein levels, synthesis, and downstream target genes.
Main Results:
- 103D5R was identified as a novel small-molecule inhibitor of HIF-1α.
- 103D5R dose- and time-dependently decreased HIF-1α protein levels without affecting other cellular proteins.
- 103D5R inhibited HIF-1 target genes (VEGF, Glut-1) and reduced HIF-1α protein synthesis, not mRNA levels or degradation.
Conclusions:
- 103D5R effectively inhibits HIF-1α protein synthesis and downstream gene activation in various cancer cells.
- The compound demonstrates potential as a therapeutic agent for targeting solid tumors by disrupting the HIF-1 pathway.
- Further research into 103D5R's mechanism of action may offer new insights for pharmacologic targeting of HIF-1α.
